| Overview |
| bs-9501R-PE |
| Factor 10 Polyclonal Antibody, PE Conjugated |
| WB |
| Human, Mouse, Rat |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Activated factor Xa heavy chain |
| 401-488/488 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2159 |
| Activated factor Xa heavy chain; Coagulation factor; Coagulation factor X; EC 3.4.21.6; F10 antibody FA10_HUMAN; Factor Xa; FX; FXA; OTTHUMP00000018735; Prothrombinase; Stuart factor; Stuart Prower factor; Stuart-Prower factor; Coagulation factor X; Factor X heavy chain. |
| Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (Prothrombin and Factors X, IX, V and VIII), which are involved in a blood coagulation cascade that leads to the formation of insoluble Fibrin clots and the promotion of platelet aggregation. Coagulation Factor X (Stuart Prower factor, FX, F10) is a vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor. The mature form of Factor X (Factor X A) is generated by Factor IX A- or Factor VII A-mediated cleavage at the tripeptide sequence, Arg-Lys-Arg, to yield a disulfide linked dimer. Together with the cofactor Factor V A and Ca2+ on the surface of platelets or endothelial cells, Factor X A coordinates as part of the prothrombinase complex, which mediates proteolysis of Prothrombin into active Thrombin. Mutations at the Factor X locus resulting in Factor X deficiencies can contribute to hemorrhagic diathesis. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz